CVS Health (NYSE:CVS) Stock Rating Lowered by Wall Street Zen

CVS Health (NYSE:CVS) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other brokerages also recently issued reports on CVS. Wolfe Research lowered their price objective on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of CVS Health in a research report on Friday, May 8th. UBS Group increased their price objective on shares of CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Sanford C. Bernstein increased their price objective on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $113.00 target price on shares of CVS Health in a research report on Monday, June 1st. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.68.

CVS Health Trading Up 1.4%

CVS opened at $101.87 on Friday. The firm’s fifty day moving average is $86.91 and its two-hundred day moving average is $80.78. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market cap of $129.98 billion, a PE ratio of 44.88, a price-to-earnings-growth ratio of 0.98 and a beta of 0.62. CVS Health has a twelve month low of $58.50 and a twelve month high of $102.77.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the prior year, the firm earned $2.25 earnings per share. The firm’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts anticipate that CVS Health will post 7.44 EPS for the current year.

Insiders Place Their Bets

In related news, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CVS. Caitong International Asset Management Co. Ltd grew its position in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the period. Swiss RE Ltd. bought a new position in shares of CVS Health in the 4th quarter valued at about $26,000. Sankala Group LLC bought a new position in shares of CVS Health in the 4th quarter valued at about $28,000. Global Trust Asset Management LLC grew its position in shares of CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after acquiring an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of CVS Health in the 4th quarter valued at about $28,000. Institutional investors own 80.66% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding access to GLP-1 weight-loss drugs, including bringing back Zepbound and loosening restrictions on newer oral therapies, which could improve customer engagement and prescription volume while supporting its broader healthcare platform. Is CVS (CVS) Using GLP-1 Access and AI Tools to Redefine Its Healthcare Moat?
• Positive Sentiment: The company is also pushing AI deeper into pharmacy, insurance, and care delivery operations, aiming to cut administrative burden, improve efficiency, and potentially widen margins over time. Healthy Returns: CVS Health executives on reducing health care’s biggest pain points
• Positive Sentiment: CVS Health has launched Aetna Mental Health on Demand, which gives members faster access to care and shows the company is trying to strengthen service offerings across its insurance business. 5 Low Price-to-Book Stocks That Are Worth Buying in June
• Positive Sentiment: Recent coverage notes CVS at a 52-week high and highlights strong post-earnings momentum, while screening screens and “trending stock” mentions suggest investor interest remains elevated. CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?
• Neutral Sentiment: CVS is also working with Fluency to move autonomous AI agents from pilot projects into production, but the financial impact is still early and not yet quantified. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Neutral Sentiment: News that Mass General Brigham and CVS are moving closer to a primary care partnership and that the stock is being heavily discussed by retail investors adds attention, but these items are not immediate earnings drivers. Mass General Brigham and CVS primary care partnership moves closer to reality
• Negative Sentiment: Musab Balbale’s departure adds some leadership turnover, though the market may view it as a limited issue unless more executive changes follow. Musab Balbale Departs CVS Health

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.